The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper

Area of Science:

• Clinical Trials Methodology
• Immunotherapy Research
• Allergen Desensitization

Background:

• Inadequate reporting of randomized controlled trials (RCTs) hinders therapeutic intervention assessment.
• The CONSORT statement aims to improve RCT reporting quality.
• Specific adaptations are needed for allergen-specific immunotherapy (ASIT) trials.

Purpose of the Study:

• To propose essential additions to the CONSORT checklist for ASIT.
• To enhance the quality and transparency of ASIT trial reporting.
• To guide the conduct and reporting of rigorous ASIT studies.

Main Methods:

• Focus on randomized, blinded, placebo-controlled Phase III trials.
• Analysis of key reporting elements for ASIT.
• Consideration of patient criteria, allergen standardization, outcomes, adverse events, and analysis.

Main Results:

• Identified critical reporting areas for ASIT within the CONSORT framework.
• Highlighted the importance of blinding patients, providers, and assessors.
• Emphasized standardization of allergens and clear outcome definitions.

Conclusions:

• Revised CONSORT guidelines are crucial for reliable ASIT research.
• Improved reporting will enhance the critical assessment of immunotherapies.
• Standardized methodology ensures the validity and reproducibility of ASIT trials.